Mental Health (MDD, MMD, Anxiety, PTSD) Flashcards

1
Q

Presentation of Psychiatric Symptoms

A
  • Usually non-specific; vague; uneasiness
  • Incumbent on practitioner to identify clusters and patterns
  • Many symptoms of common psychiatric disorders have a
    somatic component
  • Important to have knowledge regarding common psychiatric
    disorders but when in doubt—refer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Chronic Medical Conditions (co- occurring)

A

Chronic pain
- Chronic illnesses i.e. RA, COPD, CA, DM, OA, Cardiac disease, Lupus,
Fibromyalgia
- Orthopedic problems which limit function i.e. chronic back pain, joint
disease
- Obesity/anorexia/chronic weight problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mood Disorders

A

Most Common psychiatric disorder (along with anxiety
disorders) to be treated in primary care settings
- Often poorly identified and difficult to treat in primary
settings
- Symptoms reduce capacity for relationships, work and
functionality
- Leading cause of sick days and low productivity
- Includes: dysthymia, depression, mania, mixed state bipolar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Depression

A

Common emotional state
- 2/3 of people who are clinically depressed go undiagnosed and untreated in the U.S.
- Exists on a continuum—bereavement, acute situational
depression, dysthymia, major depressive disorder
- Age and cultural differences affect behavioral manifestations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Incidence & demographics

A

Depression has lifetime prevalence of 24% for women and
15% for men
- 15 million adults in U.S. each year
- Estimated between 5%-13% of all adults in primary care
settings have major depressive disorder (MDD)
- MDD assoc with high mortality; 15% will commit suicide
- Leading cause of disability; associated with morbidity and
mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Depressive Disorders

A

PCP is often the gatekeeper for persons with depression
- Becomes pathological if……
- It is disproportionate to events and sustained over a significant
time period
- It significantly impairs normal social functioning
- It significantly impairs normal somatic functioning i.e. vegetative
symptoms such as appetite, sleep, interest, motivation,
relationships
- It is seemingly unrelated to any identifiable precipitant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Major Depressive Disorder (MDD)

A

Complex brain-based illness with a primary characteristic of
a persistent disturbance in mood
###Excessive or distorted degree of sadness; manifests with
behavioral, affective, cognitive and somatic symptoms
- Etiology—multiple theories range from psychological to
neuro-biological
- Endrocrine dysfunction (HPA)
- Neurotransmitter dysfunction (5HT, NE)
- Genetic
- early attachment, trauma, etc.
- Psycho-social stressors, level of resilience, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MDD Risk and Screening

A

Disease course is variable; often chronic in nature
- Risk factors include: family hx, prior episode of MDD, female (>50), postpartum, chronic illness co-morbidity, single, significant environmental stressors, childhood trauma, high utilizer of medical care, chronic pain
- Major depression is 2-3 more times as prevalent in primary
care settings than in general pubic
- American College of Preventive Medicine (ACPM) recommends
screening and appropriate treatment for depression at the primary
care level
- Screen by asking 2 questions:
- Over the past month, have you felt down, depressed or hopeless?
- Over the past month, have you felt little interest or pleasure in
doing things?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Symptoms & Presentation MDD

A
  • Get detailed hx; social, medical, family
  • Characteristic low energy is common; mood described as
    blah, empty, discouraged, blue, down in the dumps
  • Sleep disturbance is almost always present;
    hyper/hyposomnia; early morning awakenings; frequent
    awakenings
  • Women often report  symptoms prior to menses
  • Weight change can be either up or down
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DSM Criteria–SIGECAPS

A

Constellation of symptoms that last for 2+ weeks, not a normal part of the patient’s behavior and include 5 of the following:

Depressed mood and/or anhedonia MUST be present

  • S—changes in SLEEP; insomnia or hypersomnia
  • I— loss or INTEREST in usual activities (ANHEDONIA)
  • G—feelings of GUILT, hopelessness
  • E—decreased ENERGY
  • C—poor CONCENTRATION
  • A—changes in APPETITE; increased or decreased
  • P—PSYCHOMOTOR slowing or agitation
  • S—SUICIDAL ideation, plans, or attempts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mental Status Exam

A

Appearance: unkempt, tired, disheveled
- Speech: underproductive, slow, monotone
- Affect: constricted, blunted, sad, anxious, irritable
- Mood: sad, depressed, hopeless, guilty, worried, anxious,
irritable
- Thought process and content: slowing, distractible,
ruminative, morbid preoccupation, suicidal ideation,
thoughts of being better off dead or not waking up
- Cognition, concentration, memory: may be impaired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Differentials

A
  • Hypothyroidism and apathetic hypothyroidism in elderly
  • Alcohol, substance abuse
  • Dementia, delirium
  • Hypercalcemia
  • Parkinson’s disease
  • Stroke, seizure disorder
  • Medications: H2 blockers, beta blockers, CNS antihypertensives, steroids
  • Major medical illness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Labs, Imaging, Other

A
  • No diagnostic test to determine depression
  • Consider CBC, TSH or TFTs, B-12, HIV test, BAL or Tox screen if indicated, LFTs, Antinuclear antibody (ANA),
    Dexamethasone suppression test (Cushing), lyme titer
  • MRI or CT scan if neuro abnormality is suspected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Susan is 48 years old, married, and a mother of 2 teenaged children, ages 13 and 16. She presents to her PCP with complaints of fatigue, muscle aches and pain, insomnia, irritability, loss of appetite, and feelings of “hopelessness.” Upon questioning, she determines that she has had these complaints for at least the past few months – if not longer. Her husband is now employed after
being laid off for 6 months – in a similar job, but with slightly lower pay. She continues to work part-time at the local library, but has recently been finding it increasingly difficult to focus on her work. Symptoms of depression can mimic all but which of the following?
a. Folate and vitamin B12 deficiency
b. Anemia
c. Hypothyroidism
d. Crohn’s disease

A

c

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

After lab work, Susan is diagnosed with hypothyroidism and prescribed thyroid hormone. After 6 weeks she returns to her PCP for routine follow-up. Although her thyroid function tests are now within normal range, her depressive symptoms persist; specifically, her energy level has somewhat improved but she continues to complain of fatigue, pain, insomnia, loss of appetite,
and feeling “hopeless”. How might you alter your treatment approach?
a. Make no changes
b. Send her for additional testing including brain CT scan and
HIV serology
c. Increase the dose of her thyroid hormone
d. Maintain thyroid hormone at this level and add an
antidepressant agent

A

c

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Typical Scenario

- 30 y/o female

A

30 y/o female presented to her PCP/NP with symptoms of frequent h.a., insomnia, feeling overwhelmed, and low
energy. Exam was unremarkable and blood workup
supported mild iron def. anemia. She returned after one
month with improvement in anemia but worsening of prior
symptoms. Pt revealed she’d been feeling sad and had little interest in prior activities she’d once enjoyed. She had some passive suicidal thoughts and poor concentration. Overall she reported feeling like a failure. There were no
recognizable losses. Stated she’d had an episode like this
prior, but without such intensity. No complaints of over productivity or euphoria. Her PCP prescribed antidepressants and referred her to psychiatry.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Clinical Management

A

Ensure patient safety; assess self-destructive/suicidal
behavior
- Anti-depressant Management
- Inform pt that therapeutic effect may take 4-6 weeks
- Psycho-ed re: side effects
- Continue for at least 8-12 months
- Identify clear measurements and engage patient to use therapy as
adjunct—the two work hand in hand
- May trigger a manic episode for those patients who are bipolar
- Refer if in doubt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Self-destructive and suicidal behavior

- Self-destructive behaviors are maladaptive measures used to restore balance when individual is overwhelmed

A
Self-destructive behaviors are maladaptive measures used to
restore balance when individual is overwhelmed
- Nail biting
- Cutting; burning
- Smoking
- Overeating
- Hair pulling
- Reckless behaviors
- Sexual indiscretions
- Alcohol/drugs
- suicide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Suicide Factoids

A

3rd leading cause of death between 15-24 yrs old

  • 7th leading cause of male deaths; 16th cause for females
  • For every 2 murders there are 3 suicides
  • More men than women die by suicide 4:1 but women attempt 3 times more often
  • Risk for elderly is under appreciated; especially in males
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Lethality assessment

Low

A

no hx of attempts; supports in place; no drugs; no

recent loss; wants help

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Lethality assessment

Moderate

A

has considered lethal method but no plan; hx of
less lethal attempts, uses substances; weighs out life/death
pros and cons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Lethality assessment

High

A

current lethal plan w/obtainable means; hx of
previous attempts; poor communication; no supports; uses
substances often to excess; depressed; wants to die; may
have impending serious loss (divorce, job loss, court, jail,
etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Protective Factors

A
  • Children in the home
  • Sense of responsibility to the family
  • Pregnancy
  • Spiritual or religious belief system
  • Reality testing intact
  • Coping/problem solving ability
  • Social supports
  • Employment or meaningful work
  • Meaningful relationships
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Levels of threat

A
  • Chronic
  • Suicidal ideation
  • Suicide threat
  • Suicidal gesture
  • Suicide attempt
  • Successful suicide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Direct Questioning

A
  • Have you ever thought of taking your own life?
  • Have you ever been so sad that you wanted to end it all?
  • How long have you been feeling this way?
  • How are you thinking of hurting/harming/killing yourself?
  • Never agree to keep clinical information a secret—get help
  • Don’t accept denial at face value—probe
  • Ask what are your reasons for living
  • Ask what has changed to improve your outlook
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Pharmacological Agents–SSRI

- Selective serotonin reuptake inhibitors (SSRI)—act primarily to serotonin in CNS

A
  • Celexa (citalopram)-20-40mg (no longer FDA approved for
    60mg)
  • Lexapro (escitalopram)-10-20mg
  • Prozac (fluoxetine)-20-60mg-energizing, long half life (CPY 450) *only FDA approved anti-depressant for children
  • Paxil (paroxetine)-20-60mg-also targets anxiety & panic;
    significant discontinuation syndrome
  • Zoloft (sertraline)-25-200mg—also anxiety and mild OCD; GI upset, headache common
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Common side effects of SSRI

A

GI upset, sexual dysfunction,

nervousness, headache, dry mouth, sleepiness, weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Which of the following agents is likely not an
appropriate antidepressant for a patient with
cardiovascular disease?
a. TCAs
b. SSRIs
c. SNRIs
d. Atypical antidepressants, such as bupropion

A

a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Pharmacological Agents–Other

SNRIs-

A
  • SNRIs-
  • Venlafaxine (Effexor)—75-375mg, energizing, significant discontinuation syndrome
  • Duloxetine (Cymbalta)—30-120mg; sig discontinuation syndrome, pain syndromes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

NDRIs

A
  • Wellbutrin (bupropion)—nervousness, HA, insomnia, smoking, ADHD, sz threshold; 150-450mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

SARI

A
  • Trazodone-50-300mg for insomnia; highly sedating; weak agent
  • Remeron (mirtazepine)
  • 15-45mg; good for those with poor sleep & appetite; weak agent
32
Q

TCAs

A

2nd line; high lethality if used in OD; cardiac & anti-cholingergic s.e.
- Elavil (pain, insomnia) 50-300mg, Anafranil (OCD) 100-250mg, Norpramin (ADHD)
100-300mg, Doxepin (insomnia) 100-300mg

33
Q

MOAIs

A

require tyramine restricted diet—hypertensive crisis

- Marplan, Nardil, Parnate, Selegiline

34
Q

The clinician administers a depression screening tool and Brett is diagnosed with depression. After some discussion, the PCP and Brett agree that he would benefit from both antidepressant medication and from psychotherapy to help him better manage his emotional stress and the challenges associated with his disease. He agrees to start taking a selective serotonin reuptake inhibitor (SSRI). According to available research, which of the following is the most salient factor when selecting an SSRI to treat Brett’s depression, in light of his diabetes?

a. Effect on quality of life
b. Side effect and tolerability profiles
c. Direct effect on glycemic control
d. Comparative efficacy in reducing depressive symptoms

A

b. Side effect and tolerability profiles

35
Q

Reasons to Refer

A
  • Patient wants psychotherapy
  • Active suicidal ideations
  • Switch to mania (bipolar)
  • Psychosis (thought disorder)
  • Dual diagnosis with substance abuse or other psych disorder
  • Treatment resistant depression
36
Q

Other depression spectrum

disorders

A
  • Dysthymia disorder
  • Adjustment disorder
  • Bereavement (complicated/unresolved)
  • Seasonal affective disorder
37
Q

Non-pharmacological treatment

for Depression

A
  • Counseling—CBT, DBT, Interpersonal Tx, Problem Solving Tx, Psychodynamic Tx plus many others
  • ECT
  • Transcranial Magnetic Stimulation
  • Phototherapy (lightbox)
38
Q

Bipolar-Manic Depressive Disorder

A
  • Should not be managed by PCP; requires referral
  • Mood disorder of both polarities
  • depression/expansive mania
  • Three patterns:
    1. Single polarity—unipolar depression may be the first signal
    2. Manic symptoms only
    3. Cyclical pattern
  • Manifests with behavioral, affective, cognitive and somatic symptoms
  • Complex genetic, biological and environmental etiologic factors
39
Q

Incidence/demographics/risk

A
  • Less common than MDD
  • 2.6% of adult U.S. population
  • Mean age of onset in mid-20s; although common in adolescent years; difficulty to tease apart from ADHD
  • Greater risk with genetic loading-1st or 2nd degree relative
40
Q

Suggestive symptoms for Manic Depressive Disorders/Mood disorders

  • Bipolar
A
  • sleep; marked difference from usual pattern
  • Inflated self esteem; grandiosity
  • Irritability most often seen in children
  • Unrestrained buying sprees,
  • Sexual indiscretions
  • Unsound business ventures
  • Excessive substance use/abuse
41
Q

Pharmacology

Bipolar

A
  • Never use antidepressant unless mood stabilizer on board
42
Q

Mood stabilizers:

Lithium

A
  • gold standard but with many clinical s.e. that require careful monitoring—tremors, weight gain, headaches, GI upset, D&V, polyuria, kidney failure if patient ODs; narrow therapeutic window (0.5-1.2); requires baseline labs; avoid in pregnancy
43
Q

Anticonvulsant agents

A

avoid in pregnancy*
- Carbamazepine* (tegretol)—agranulocytosis, nausea,
dizziness, dry mouth, sedation
- Valproic acid, divalproex* (depakote)—(500-1500mg) nausea, diarrhea, abd cramps, sedation, tremor; hair loss; check LFTs; check levels (50-124)
- Lamotrigine (lamictal)—dizziness, somnolence, nausea, headache, hepatotoxicity, Stevens-Johnson-25-600mg slowly titrate up
- Topiramate (topamax)—50-1000mg—somnolence, fatigue, altered cognition; nausea

44
Q

Anxiety Disorder

A
  • Most common of all psychiatric disorders
  • Etiology—multiple theories, psychodynamic, interpersonal, neurobiological
  • Can initially present as medical disorders; high degree of somatic symptomatology; often confused with respiratory or cardiac disorders
  • Co-morbidity frequently exists with substance abuse,
    depression and eating disorders
  • Differentiate between normal levels and pathological levels of anxiety
  • Sustained over a significant time frame
  • Significantly impairs functioning
  • Unrelated to any identifiable event/situation
45
Q

Assessment includes

A
  • detailed HPI, social hx, med hx including OTC, vitamins, supplements, prescription; substance use/abuse for self medicating; caffeine use
  • Assess for psychological symptoms of anxiety such as
  • Fear of dying, losing one’s mind, sense of unreality
  • Belief that he/she is very ill but without findings to support
  • Excessive worry
46
Q

Work-up

A
  • Patients may present to ED if they experience a panic attack
  • If there are abnormal physical findings on exam such as a goiter, prominent nystagmus or clinician suspects toxic ingestion, labs will r/o pxs such as drug induced causes, systemic infections, toxins, electrolyte or endocrine disturbances
  • Imaging usually not necessary
  • EKG—r/o for dysrhythmias or adverse med effects such as QT elongation
47
Q

Pharmacological management- Anxiety

A
  • SSRIs considered 1st line—act on serotonin system and indirectly on GABA system; takes time to reach symptom control; best used with psychotx
  • Benzodiazepines—potentiate GABA effects; rapid onset; limit to lowest possible dose; short term use; commonly leads to dependency and tolerance; contraindicated in substance abuse pts; all have street value
  • BNZ with longer ½ lives require less frequent dosing, have severe w/d and less rebound anxiety—klonopin (clonazepam), valium (diazepam)
  • BNZ with shorter ½ lives require more frequent dosing, have more severe w/d and rebound anxiety
  • ativan (lorazepam), xanax (alprazolam)—quick onset;
    less drug accumulation but increased risk of addiction
48
Q

Other Anxiet Tx

A
  • Buspar (buspirone)—20-60mg—regular dosing, no prns—helpful adjunct
  • Gabitril (tiagiabine)—4-56mg—helpful adjunct for anxiety;
  • Neurontin (gabapentin)—300-3600mg—anxiety, neuropathic pain, fibromyalgia, anti-craving—now has street value
  • Clonidine (0.1mg) qd or bid; watch for bp changes—now has street value
49
Q

Panic Disorder

A
  • Discrete episodes or attacks with sudden onset of intense apprehension, fearfulness or terror often assoc. with feelings of impending doom
    Differentials (Hyperthyroidism, hyperparathyroidism, pheochromocytosis, vestibular dysfunction, sz disorders, cardiac arrhythmias, use of CNS stimulants (coc, amphet, caffeine)
  • Associated with anxiety disorders, phobias, PTSD
  • Pharm mgmt—same as anxiety disorders
50
Q

Trauma and Stress Disorders

A
  • Trauma exposure relatively common experience
  • Est. 2/3 of U.S. adults over their lifetime If direct and indirect exposure are both included in definition, then 89% of Americans have been exposed over their lifetime
  • Those who are less resilient may suffer effects that persist over time
51
Q

Trauma Responses

A
  • Depression
  • Anxiety disorders
  • Adjustment disorders
  • Substance misuse
  • Acute stress disorder (ASD)
  • Posttraumatic stress disorder (PTSD)
52
Q

Acute Stress Disorder Diagnosis—DSM 5

A
  • *** Exposure to actual or threatened death, serious injury, or sexual violation
  • Presence of 9 or more symptoms from following categories
  • Intrusion
  • Negative mood
  • Dissociation
  • Avoidance
  • Arousal
  • ***Duration is 3 days to 1 month after trauma exposure
  • Must cause clinically significant distress or impairment in functioning
  • Symptoms can not be attributable to substances or medical conditions
53
Q

Goals of Treatment

A
  • Reduce severity of symptoms
  • Prevent or treat trauma related co-morbid conditions
  • Improve adaptive functioning
  • Prevent relapse
  • Integrate trauma into the patient’s life story
  • Prevent the development of PTSD
54
Q

Course of Acute Stress Disorder

A
  • 80% of people with ASD develop PTSD
  • Factors assoc w/ increase risk include:
  • Female, prior trauma, low levels of social support, fx hx of psychopathology, past and new occurrence of stressors
55
Q

PTSD

A
  • Exposure to actual or threatened death, serious injury, or sexual violence—direct, learning of, witnessing, repeated exposure to details
  • Recurrent intrusive memories, dreams, flashbacks
  • Negative alterations in cognition and mood
  • Marked alterations in arousal and reactivity associated with the event
  • Persistent avoidance of stimuli that arouse recollection of the event
56
Q

Management

A
  • Symptoms often consistent with anxiety/depression;
    differentials are similar
  • Often have co-morbid substance abuse/dependence pxs; self-medication
  • May become psychotic depending on degree of distress
  • Follow guidelines for clinical mgmt of anxiety
  • Refer to Psych
  • CBT; relaxation tx, supportive group tx, eye movement
    desensitization and reprocessing (EMDR)
57
Q

Thought disorders and Anti-psychotic medications

A
  • Many agents used in combination with other psychiatric medicines
  • Not commonly prescribed by PCP but may be seen quite commonly as part of the patient’s profile
  • Newer agents, 2nd generation atypicals are better tolerated but have significant side effects—should be closely monitored
  • Pharmacological tx is the primary treatment modality for patients with psychotic disorders
58
Q

Atypicals

A
  • 1st line; fewer neurological s.e.; effect both the positive
    (hallucinations, delusions) and negative (amotivation, apathy) symptoms
  • Function as serotonin-dopaminergic antagonists
  • D2 and 5HT2a blockade
  • Not known to cause TD
  • EPS is much less common
  • Major side effect pxs related to development of metabolic syndrome, DM, hypercholesteremia
  • Prolactin elevation common** review EPS
59
Q

Clozapine (clozaril)- atypicals

A
  • 25mg-900mg—used for treatment resistant schizophrenia; WBC weekly x 6 mos, then monthly
60
Q

Quetiapine (seroquel)- atypicals

A
  • Quetiapine (seroquel)-25-800mg—sedation, weight gain, often used for anxiety and sleep
61
Q

Olanzepine (zyprexa)- atypicals

A

5-20mg—sedation, weight gain, hyperlipidemia, gluocose

62
Q

Risperdone (risperdal)- atypicals

A

Risperdone (risperdal)-0.5-6mg—doses, 6mg assoc with EPS, prolactin elevation; Consta is injectable formulation

63
Q

Ziprasidone (geodon)- atypicals

A

Ziprasidone (geodon)-40-160mg—sedation, dizziness prolongation of QT interval; must take with food; can be used with mania as well

64
Q

Aripiprazole (abilify)- atypicals

A

Aripiprazole (abilify)-5-20mg—agitation, insomnia, somnolence, akathesia, weight gain, elevated lipids, often used as adjunct with treatment resistant depression

65
Q

More (newer) Agents

A

More (newer) Agents

66
Q

Fanapt (iloperidone)

A

Fanapt (iloperidone) 1mg-12mg bid (taper upwards) mood stabilizer; little or no akathisia; Potent alpha 1 blocking properties suggest potential utility in PTSD
(e.g., nightmares, as for prazosin)

67
Q

Latuda (lurasidone)

A

Latuda (lurasidone) 40-80mg qd-may be useful for cognitive issues Absorption decreased by 50% unless taken with food; metabolically friendly; does not
cause QTc prolongation; category B for pregnancy; somnolence, akathesia common;Lower EPS

68
Q

Saphris (asenapine)

A

Saphris (asenapine) 5mg qd-10mg bid—sublingual formulation. Approved 2009 for schizophrenia and bipolar; needs to be taken by dissolving it under
your tongue; If swallowed, only 5% is metabolized

69
Q

Invega (paliperidone) or Sustenna (IM formulation)

A

Invega (paliperidone) or Sustenna (IM formulation) Sustained release formulation-qd dosing; lower peak-dose plasma levels and thus lower EPS/sedation

70
Q

Typical Anti-psychotics

A
  • Useful for treating positive symptoms by blocking dopamine; can make negative symptoms worse
  • Inexpensive; have injectable forms; Prolixin, Haldol
    Hi-potency– risk of EPS but less sedation/anti-cholinergic effects; Haldol, Prolixin, Trilafon, Stelazine, Navane
  • Lo-potency–risk of EPS but more sedation and anticholinergic effects; Thorazine, Mellaril (prolonged QT)
  • Common S.E.—orthostatic hypotension; dry mouth, blurred vision, constipation, urinary retention, weight gain, lowering of sz threshold, photo sensitivity
71
Q

Extra pyramidal symptoms

A

Extra pyramidal symptoms
- Caused by D2 receptor antagonism
- When dopamine receptors are blocked, Ach (which causes EPS)
- Compazine—antiemetic; phenothiazine derivative; may precipitate acute dystonia
Treated by use of anti-Parkinsonian drugs
- Anticholinergics—cogentin, artane
- Antihistamines—benadryl
- Dopamine agonists—amantadine
- Benodiazepines—klonopin, ativan
- Beta-blocker—propranolol
- Alpha 2 agonist—clonidine

72
Q

Akathesia

A

Akathesia- motor restlessness; inability to sit still; rocking, pacing, subjective sense of restlessness

73
Q

Akinesia

A

Akinesia- absence of movement; difficulty initiating motion, often
mistaken for laziness or lack of interest/motivation

74
Q

Dystonia

A

Dystonia- muscle spasm; spasticity of muscle group esp neck or back; can be mistaken for agitation or stereotypic movements

75
Q

Pseudo-parkinson’s

A

Pseudo-parkinson’s-produced by d-blockade; shuffling gait, motor slowing, mask-like, pill rolling, tremors, muscle rigidity

76
Q

Tardive dyskinesia (TD)

A

Tardive dyskinesia (TD)-involuntary abnormal muscle
movement of the mouth, tongue, face, jaw and trunk; irreversible can sometimes occur with use of typical anti-psychotics
- Lip-smacking, chewing, tongue protrusion, twisting
movement of the trunk or limbs
- AIMS (Abnormal Involuntary Movement Scale) q 6mos
- Assess gait, sitting with feet on floor, sitting with hands hanging, arms outstretched in front, touching thumb to each finger, open
mouth and protrude tongue, flexing and extending arms
- Assess presence and degree of functional impairment